neod001
mAbexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Apr 1, 2013 (NCT01707264)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
- Light chain aggregatesINHIBITOR
Light chain aggregates inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833345 ↗
Also known as
- neod001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04973137 | Phase 3 | Aug 30, 2021 | Prothena Biosciences Inc |
| NCT03154047 | Phase 2 | Jun 30, 2017 | Prothena Biosciences Inc |
| NCT03168906 | Phase 2 | Jun 1, 2017 | Tufts University |
| NCT02632786 | Phase 2 | Mar 1, 2016 | Prothena Biosciences Inc |
| NCT02613182 | Phase 2 | Feb 1, 2016 | Prothena Biosciences Inc |
| NCT02312206 | Phase 3 | Feb 1, 2015 | Prothena Biosciences Inc |
| NCT01707264 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | Prothena Biosciences Inc |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Prothena Biosciences Inc | For profit | 6 | 6 | 2 | 2013 |
| Tufts University | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1